Compare AJANTA PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FULFORD INDIA AJANTA PHARMA/
FULFORD INDIA
 
P/E (TTM) x 22.0 398.8 5.5% View Chart
P/BV x 3.8 6.2 61.1% View Chart
Dividend Yield % 0.9 0.1 1,096.9%  

Financials

 AJANTA PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
FULFORD INDIA
Mar-14
AJANTA PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,422942 150.9%   
Low Rs898450 199.5%   
Sales per share (Unadj.) Rs233.5691.4 33.8%  
Earnings per share (Unadj.) Rs44.011.5 383.6%  
Cash flow per share (Unadj.) Rs52.215.4 339.6%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.3 270.1%  
Book value per share (Unadj.) Rs255.1380.0 67.1%  
Shares outstanding (eoy) m88.023.90 2,256.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.01.0 493.4%   
Avg P/E ratio x26.460.7 43.4%  
P/CF ratio (eoy) x22.245.3 49.1%  
Price / Book Value ratio x4.51.8 248.2%  
Dividend payout %20.517.4 117.3%   
Avg Mkt Cap Rs m102,0812,714 3,760.7%   
No. of employees `0006.80.4 1,531.5%   
Total wages/salary Rs m4,307505 852.9%   
Avg. sales/employee Rs Th3,022.66,073.0 49.8%   
Avg. wages/employee Rs Th633.41,137.4 55.7%   
Avg. net profit/employee Rs Th569.1100.7 565.3%   
INCOME DATA
Net Sales Rs m20,5542,696 762.3%  
Other income Rs m211125 168.1%   
Total revenues Rs m20,7652,822 735.9%   
Gross profit Rs m5,664-46 -12,207.5%  
Depreciation Rs m72115 4,742.1%   
Interest Rs m1210 122.1%   
Profit before tax Rs m5,14354 9,470.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,27310 13,260.4%   
Profit after tax Rs m3,87045 8,657.0%  
Gross profit margin %27.6-1.7 -1,601.5%  
Effective tax rate %24.817.7 140.0%   
Net profit margin %18.81.7 1,135.7%  
BALANCE SHEET DATA
Current assets Rs m11,8121,738 679.5%   
Current liabilities Rs m3,776545 693.3%   
Net working cap to sales %39.144.3 88.3%  
Current ratio x3.13.2 98.0%  
Inventory Days Days7748 159.7%  
Debtors Days Days824 1,895.5%  
Net fixed assets Rs m14,39812 120,995.0%   
Share capital Rs m17539 449.7%   
"Free" reserves Rs m22,2771,443 1,543.8%   
Net worth Rs m22,4521,482 1,515.0%   
Long term debt Rs m70-   
Total assets Rs m26,9622,077 1,298.3%  
Interest coverage x444.36.7 6,616.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.3 58.7%   
Return on assets %14.42.6 551.6%  
Return on equity %17.23.0 571.4%  
Return on capital %23.04.3 533.1%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m10,68217 62,102.9%   
Fx outflow Rs m2,102673 312.2%   
Net fx Rs m8,580-656 -1,308.0%   
CASH FLOW
From Operations Rs m3,74890 4,164.2%  
From Investments Rs m-2,228105 -2,130.0%  
From Financial Activity Rs m-1,475-14 10,458.2%  
Net Cashflow Rs m45181 25.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 3.8 40.8%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.2 80.2%  
Shareholders   20,968 4,783 438.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  SUVEN LIFESCIENCES  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 19, 2019 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - STERLING BIOTECH COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS